Aktuelle Version vom 1. Dezember 2020, 16:34 Uhr
by explicit search dec/01/2020
| 32514047 ä. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)
|
90% der pmbc sind MDSC in cov !!!!!
| C7590570 2020. Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome
|
| 32935120 ä. Metabolic programs define dysfunctional immune responses in severe COVID-19 patients
|
2 pop. MDSC in active cov
| 32759007 2020. Prostaglandin D2 as a mediator of lymphopenia and a therapeutic target in COVID-19 disease
|
PGD2 stim MDSC
| 32952595 2020. Ramatroban as a Novel Immunotherapy for COVID-19
|
PGD2 antagonist inhibits MDSC
| 32951474 ä. Potential alteration of COVID-19 by beta-mercaptoethanol
|
mdsc quench cysteine depleteing gsh thus immunosupp. bme repletes
32977223 2020. Immunological features of coronavirus disease 2019 in patients with cancer co+cancer+ have many mMDSC
32407466 ä. An inflammatory profile correlates with decreased frequency of cytotoxic cells in COVID-19 MDSC in cov.
C7574992 2020. The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing MDSC-like cells
32908980 ä. Induction of a regulatory myeloid program in bacterial sepsis and severe COVID-19 MS1 MDSC-like monocytoid cells.
33185926 2020. SARS-CoV-2-mediated immune system activation and potential application in immunotherapy something
32561657 2020. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection? by induction of MDSC ????
